Health News Releases

February 02, 2024 14:40

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-to-date strong momentum in its Growth & Launch Prod

February 01, 2024 15:30

DEKA Plays Its Poker Quad With Four New Laser Platforms at IMCAS Paris, the World Dermatology and Plastic and Aesthetic Surgery Congress

DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics

February 01, 2024 11:35

Quanta System unveils the latest breakthrough technology drawn on its picosecond laser heritage: VarioPulse Technology®, the next-level device for the next-level experts

Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of p

January 31, 2024 14:10

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53888524&newsitemid=20240127162836&lan=en-US&anchor=%28TSE%3A4502%2FNY

January 31, 2024 11:50

PQE Group: 100+M€ in Revenues

PQE Group (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww2.pqegroup.com%2F&esheet=53889015&newsitemid=20240129526587&lan=en-US&anchor=PQE+Group&index=1&md5=5321f09b4f01e443d0714

January 30, 2024 14:06

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53887989&newsitemid=20240125010746&lan=en-US&anchor=TSE%3A4502%2FNYSE%

January 28, 2024 10:30

New Independent Clinical Study Showcases Safety and Efficacy of GC Aesthetics’ PERLE Breast Implant

GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce that its breast implant, PERLE™,

January 26, 2024 13:30

Kenvue Declares Quarterly Cash Dividend

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter

January 26, 2024 11:20

Variational AI Announces Generative AI Project With Merck

Variational AI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvariational.ai%2F&esheet=53887584&newsitemid=20240125917133&lan=en-US&anchor=Variational+AI&index=1&md5=29326fc2ebf897

January 26, 2024 09:30

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in

January 25, 2024 16:05

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl an

January 25, 2024 15:10

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologics™, to represent the company’s antibody discovery business division

January 25, 2024 10:05

BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt wil

January 24, 2024 15:20

Crown Bioscience’s Global Oncology Research Facilities Achieve Prestigious ISO and CAP Accreditations

Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=53885224&newsitemid=20240123812070&lan=en-US&anchor=Crown+Bioscience&index=1&md5=6c8d045a

January 23, 2024 11:50

Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Merck, a leading science and technology company, today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENC

January 22, 2024 15:35

Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region

Galderma, the emerging pure-play dermatology category leader, announced today it has received approval from Health Canada for Restylane® SHAYPE™, a hyaluronic acid (HA) injectable designed for tempora

January 19, 2024 17:35

New Blue Shift Report From Arthur D. Little Assesses the Future of Synthetic Biology

Arthur D. Little (ADL) has published The Brave New World Of Synthetic Biology, the latest in a series of leading edge reports from the company’s Blue Shift institute, which explore the impact of new t

January 19, 2024 15:40

Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the Field of CLIA Based Immunoassay

Fujirebio Holdings, Inc. and Agappe Diagnostics Ltd today announced that they have entered into an agreement of Contract Development and Manufacturing Organization (CDMO) partnership for Cartridge bas

January 19, 2024 15:00

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the “Board of Directors”) unani

January 19, 2024 14:45

Hyperice Expands IP Enforcement Action, Files Percussion Patent Infringement Lawsuits Against Sharper Image, HoMedics, Ekrin Athletics, and Over a Dozen Others

Hyperice (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhyperice.com%2F&esheet=53883981&newsitemid=20240118052531&lan=en-US&anchor=Hyperice&index=1&md5=50225aea35cb318a90a877e8ce65

January 19, 2024 14:15

ELIQUENT Life Sciences Announces Acquisition of European-Focused Regulatory Partner: RApport Global Strategic Services

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm for the life sciences industry, today announced the acquisition of RApport Global Strategic Services (RApport). RApport is a UK b

January 19, 2024 11:00

Takeda Named Global Top Employer for Seventh Consecutive Year

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53884185&newsitemid=20240118372418&lan=en-US&anchor=Takeda&index=1&md5=60021b3805d222a8a4d5481a478ebf

January 18, 2024 16:55

Timeline, a Swiss Longevity Biotech, Secures Pivotal Financing Round with Support from Strategic Global Industry Leaders, including L’Oréal and Nestlé

Timeline, a consumer health biotech company at the forefront of developing innovative solutions for healthy aging and longevity, today announces that it raised CHF 56M (USD 66M) in an oversubscribed S

January 18, 2024 15:15

PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by

January 17, 2024 15:57

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral

News by Region

News by Industry